KR102151290B1 - 1―［1―（벤조일）―피롤리딘―2―카보닐］―피롤리딘―2―카보니트릴 유도체 - Google Patents

1―［1―（벤조일）―피롤리딘―2―카보닐］―피롤리딘―2―카보니트릴 유도체 Download PDF

Info

Publication number
KR102151290B1
KR102151290B1 KR1020157015736A KR20157015736A KR102151290B1 KR 102151290 B1 KR102151290 B1 KR 102151290B1 KR 1020157015736 A KR1020157015736 A KR 1020157015736A KR 20157015736 A KR20157015736 A KR 20157015736A KR 102151290 B1 KR102151290 B1 KR 102151290B1
Authority
KR
South Korea
Prior art keywords
formula
pyrrolidine
compound
carbonyl
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157015736A
Other languages
English (en)
Korean (ko)
Other versions
KR20150082634A (ko
Inventor
어니스트 지랄트 레도
테레사 탈라고 크루아
로저 프라데스 코사노
솔레다드 로요 그라시아
Original Assignee
유니버시테이트 드 바르셀로나
펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나)
이프로테오스 에스.엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시테이트 드 바르셀로나, 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나), 이프로테오스 에스.엘 filed Critical 유니버시테이트 드 바르셀로나
Publication of KR20150082634A publication Critical patent/KR20150082634A/ko
Application granted granted Critical
Publication of KR102151290B1 publication Critical patent/KR102151290B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Epidemiology (AREA)
KR1020157015736A 2012-11-12 2013-11-11 1―［1―（벤조일）―피롤리딘―2―카보닐］―피롤리딘―2―카보니트릴 유도체 Active KR102151290B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382446.8 2012-11-12
EP12382446.8A EP2730571A1 (en) 2012-11-12 2012-11-12 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
PCT/EP2013/073460 WO2014072498A1 (en) 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Publications (2)

Publication Number Publication Date
KR20150082634A KR20150082634A (ko) 2015-07-15
KR102151290B1 true KR102151290B1 (ko) 2020-09-03

Family

ID=47278735

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157015736A Active KR102151290B1 (ko) 2012-11-12 2013-11-11 1―［1―（벤조일）―피롤리딘―2―카보닐］―피롤리딘―2―카보니트릴 유도체

Country Status (25)

Country Link
US (2) US10125097B2 (enExample)
EP (2) EP2730571A1 (enExample)
JP (1) JP6203278B2 (enExample)
KR (1) KR102151290B1 (enExample)
CN (1) CN104903314B (enExample)
AU (1) AU2013343430B2 (enExample)
BR (1) BR112015010377A8 (enExample)
CA (1) CA2890042C (enExample)
CY (1) CY1118818T1 (enExample)
DK (1) DK2917209T3 (enExample)
EA (1) EA028422B1 (enExample)
ES (1) ES2621672T3 (enExample)
HR (1) HRP20170485T1 (enExample)
HU (1) HUE032472T2 (enExample)
LT (1) LT2917209T (enExample)
ME (1) ME02706B (enExample)
MX (1) MX367488B (enExample)
NZ (1) NZ709096A (enExample)
PL (1) PL2917209T3 (enExample)
PT (1) PT2917209T (enExample)
RS (1) RS55865B1 (enExample)
SI (1) SI2917209T1 (enExample)
SM (1) SMT201700202T1 (enExample)
WO (1) WO2014072498A1 (enExample)
ZA (1) ZA201504269B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
EP3031458A1 (en) * 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
SG11202005563YA (en) 2017-12-15 2020-07-29 Praxis Biotech LLC Inhibitors of fibroblast activation protein
JP2022514352A (ja) 2018-12-21 2022-02-10 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
EP4178945B1 (en) * 2020-07-07 2024-08-28 Accure Therapeutics, S.L. 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
MY208099A (en) 2020-12-28 2025-04-15 Sarawak Biodiversity Council Compound for treating neurodegenerative diseases and its isolation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018891A1 (en) * 1990-06-04 1991-12-12 Pfizer Inc. Aromatic pyrrolidine and thiazolidine amides
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
HUT76640A (en) * 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
AU2001270627A1 (en) * 2000-07-19 2002-01-30 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
FI20011466A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
JP4630192B2 (ja) 2003-09-24 2011-02-09 日本化薬株式会社 プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.
EP2389176A4 (en) * 2009-01-23 2012-08-01 Univ Sydney NEW THERAPY FOR METABOLISM DISEASE
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Also Published As

Publication number Publication date
US10611727B2 (en) 2020-04-07
EA201590942A1 (ru) 2015-10-30
CN104903314B (zh) 2018-06-05
ME02706B (me) 2017-10-20
NZ709096A (en) 2018-04-27
RS55865B1 (sr) 2017-08-31
JP2015536965A (ja) 2015-12-24
JP6203278B2 (ja) 2017-09-27
BR112015010377A8 (pt) 2018-01-16
EP2730571A1 (en) 2014-05-14
AU2013343430B2 (en) 2017-05-25
PT2917209T (pt) 2017-03-31
SI2917209T1 (sl) 2017-05-31
US20190084927A1 (en) 2019-03-21
EP2917209B1 (en) 2017-02-08
HRP20170485T1 (hr) 2017-06-02
US10125097B2 (en) 2018-11-13
PL2917209T3 (pl) 2017-09-29
AU2013343430A1 (en) 2015-07-02
KR20150082634A (ko) 2015-07-15
ES2621672T3 (es) 2017-07-04
WO2014072498A1 (en) 2014-05-15
BR112015010377A2 (pt) 2017-07-11
DK2917209T3 (en) 2017-04-18
HK1214597A1 (en) 2016-07-29
LT2917209T (lt) 2017-04-25
MX367488B (es) 2019-08-20
HUE032472T2 (en) 2017-10-30
US20160168088A1 (en) 2016-06-16
CY1118818T1 (el) 2018-01-10
EA028422B1 (ru) 2017-11-30
MX2015005931A (es) 2016-02-05
EP2917209A1 (en) 2015-09-16
CA2890042A1 (en) 2014-05-15
ZA201504269B (en) 2016-09-28
CN104903314A (zh) 2015-09-09
SMT201700202T1 (it) 2017-05-08
CA2890042C (en) 2021-06-01

Similar Documents

Publication Publication Date Title
US10611727B2 (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
JP6471163B2 (ja) 細胞壊死阻害剤としてのインドールアミド化合物
US12459891B2 (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK1214597B (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
RU2841064C1 (ru) 1-[1-(4-бензилокси-3,5-дифтор-бензоил)-4-фтор-пирролидин-2-карбонил]-пирролидин-2-карбонитрил
HK40084881B (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK40084881A (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
CN119451944A (zh) Prep结合配体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6